← Back to Clinical Trials
Recruiting NCT06738134

NCT06738134 Differentiated Service Delivery (DSD) for People Living with HIV (PLHIV) and Comorbidities

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06738134
Status Recruiting
Phase
Sponsor Chinese University of Hong Kong
Condition Delivery of Health Care
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2024-05-01
Primary Completion 2026-03-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 300 participants in total. It began in 2024-05-01 with a primary completion date of 2026-03-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is an implementation study evaluating differentiated service delivery model for the care of comorbidities for people living with HIV (PLWH). The Hybrid Type 3 study design is adopted, with the primary goal of evaluating implementation outcomes, and secondary goals of evaluating service and client outcomes according to the Reach, Effectiveness, Adoption, Implementation and Maintenance (RE-AIM) framework, including Proctor's Conceptual Framework for Implementation Outcomes, using mixed methods for data collection and analyses. PLWH will be identified from the Integrated Treatment Centre, an HIV clinic in Hong Kong, which provides care to around 3500 PLWH, with services including out-patient care of patients with human immunodeficiency virus (HIV) infection, antiviral therapy for HIV and hepatitis co-infection, and treatment of sexually transmitted diseases. PLWH with comorbidities will be asked to participate in a survey for willingness to participate. Those interested will be co-managed at the HIV Comorbidities Clinic at the Prince of Wales Hospital, where the DSD model of care is conducted. Evaluation of implementation outcomes will be performed at the end of the programme.

Eligibility Criteria

Inclusion Criteria: * PLWH eligible to participate in this study are PLWH aged 18 years or above * followed up at the HIV Clinic, and with one or more cardiometabolic comorbidities, including hypertension, diabetes, hyperlipidaemia, metabolic-associated fatty liver disease, cardiovascular diseases, and cerebrovascular diseases. They will be eligible if HIV physicians consider them having sub-optimal control of their comorbidities, suspected of having complications, or would benefit from screening of complications resulting from their comorbidities. These indications are selected as they involve specialist care, including investigations and treatment, which are not available at the HIV Clinic. Exclusion Criteria: * Incompetent subjects who cannot give informed written consent.

Contact & Investigator

Central Contact

Grace LUI

✉ gracelui@cuhk.edu.hk

📞 35051716

Principal Investigator

Grace LUI

PRINCIPAL INVESTIGATOR

Chinese University of Hong Kong

Frequently Asked Questions

Who can join the NCT06738134 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Delivery of Health Care. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06738134 currently recruiting?

Yes, NCT06738134 is actively recruiting participants. Contact the research team at gracelui@cuhk.edu.hk for enrollment information.

Where is the NCT06738134 trial being conducted?

This trial is being conducted at Shatin, Hong Kong.

Who is sponsoring the NCT06738134 clinical trial?

NCT06738134 is sponsored by Chinese University of Hong Kong. The principal investigator is Grace LUI at Chinese University of Hong Kong. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology